Literature DB >> 7957808

Specific antiplatelet autoantibodies in patients with antiphospholipid antibodies and thrombocytopenia.

F Fabris1, A Steffan, I Cordiano, P Borzini, G Luzzatto, M L Randi, A Girolami.   

Abstract

By means of immunoblotting and monoclonal antibody immobilization of platelet antigens (MAIPA) we have studied the specificity of antiplatelet antibodies in patients with antiphospholipid antibodies and thrombocytopenia defined as presence of anticardiolipin IgG and a platelet count below 100 x 10(9)/l. The study group consisted of 10 patients with systemic lupus erythematosus (SLE), 8 patients with primary anti-phospholipid syndrome (PAPS) and 16 patients with idiopathic thrombocytopenic purpura (ITP). The comparison group was formed by 17 patients with classical chronic ITP without anticardiolipin IgG. We identified the 80-100, 130-150 and 150-170 KD surface proteins that comigrate with GPIIIa, GPIIb and GPIb and a 50-70 KD cytoplasm band by immunoblot. In patients with classical chronic ITP, the prevalence of the antiplatelet antibodies against GPIIIa was 53% on immunoblot assay and 47% on MAIPA. In ITP patients who had also anti-phospholipid antibodies in serum, the percentage of reactivity to GPIIIa declined to 37% on immunoblot and 21% on MAIPA but it was not statistically different from the percentage observed in patients with classical ITP. Autoantibodies to platelet surface glycoproteins were almost absent in SLE and PAPS patients, who showed a significant prevalence (78%) of IgG reactivity to the 50-70 KD internal platelet protein which was frequently encountered also in patients with ITP and aPL (56%). Our study provides additional evidence that platelet antigens in patients with phospholipid-associated secondary immune thrombocytopenia are different from those of primary ITP, and that surface glycoproteins were not involved.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7957808     DOI: 10.1111/j.1600-0609.1994.tb00195.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  9 in total

1.  Antiplatelet glycoprotein autoantibodies in patients with autoimmune diseases with and without thrombocytopenia.

Authors:  I Cordiano; F Salvan; M L Randi; M A Ruffatti; A Steffan; A Girolami; F Fabris
Journal:  J Clin Immunol       Date:  1996-11       Impact factor: 8.317

Review 2.  The significance and management of thrombocytopenia in antiphospholipid syndrome.

Authors:  Bahar Artim-Esen; Reyhan Diz-Küçükkaya; Murat İnanç
Journal:  Curr Rheumatol Rep       Date:  2015-03       Impact factor: 4.592

Review 3.  The non-haemostatic role of platelets in systemic lupus erythematosus.

Authors:  Petrus Linge; Paul R Fortin; Christian Lood; Anders A Bengtsson; Eric Boilard
Journal:  Nat Rev Rheumatol       Date:  2018-03-21       Impact factor: 20.543

Review 4.  Haematological manifestations of lupus.

Authors:  Anum Fayyaz; Ann Igoe; Biji T Kurien; Debashish Danda; Judith A James; Haraldine A Stafford; R Hal Scofield
Journal:  Lupus Sci Med       Date:  2015-03-03

Review 5.  Cryptic conspirators: a conversation about thrombocytopenia and antiphospholipid syndrome.

Authors:  Andrew P Vreede; Paula L Bockenstedt; W Joseph McCune; Jason S Knight
Journal:  Curr Opin Rheumatol       Date:  2019-05       Impact factor: 5.006

Review 6.  [Antiphospholipid antibody syndrome].

Authors:  R Schmidt; E H Scheuermann; A Viertel; H Geiger; I Scharrer
Journal:  Med Klin (Munich)       Date:  1999-02-15

Review 7.  Pathobiology of secondary immune thrombocytopenia.

Authors:  Douglas B Cines; Howard Liebman; Roberto Stasi
Journal:  Semin Hematol       Date:  2009-01       Impact factor: 3.851

Review 8.  Lupus thrombocytopenia: pathogenesis and therapeutic implications.

Authors:  Nikolaos Galanopoulos; Anna Christoforidou; Zoe Bezirgiannidou
Journal:  Mediterr J Rheumatol       Date:  2017-03-28

9.  Eltrombopag-Induced Thrombocytosis and Thrombosis in Patients With Antiphospholipid Syndrome and Immune Thrombocytopenic Purpura.

Authors:  Zayar Oo; Kapilkumar Manvar; Jen Chin Wang
Journal:  J Investig Med High Impact Case Rep       Date:  2022 Jan-Dec
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.